公开(公告)号：JP2002179652A

公开(公告)日：2002-06-26

申请号：JP2001319183

申请日：2001-10-17

Applicant: SERVIER LAB

Inventor： METH-COHN OTTO ,  YU CHU-YI ,  LESTAGE PIERRE ,  LEBRUN MARIE-CECILE ,  CAIGNARD DANIEL-HENRI ,  RENARD PIERRE

IPC: C07D211/00 ,  A61K31/435 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/4418 ,  A61K31/4425 ,  A61K31/4439 ,  A61K31/445 ,  A61K31/4458 ,  A61K31/451 ,  A61K31/452 ,  A61K31/5377 ,  A61P25/00 ,  A61P25/02 ,  A61P25/04 ,  A61P25/16 ,  A61P25/28 ,  B01J23/42 ,  C07B61/00 ,  C07D211/22 ,  C07D211/32 ,  C07D213/30 ,  C07D213/36 ,  C07D213/38 ,  C07D213/50 ,  C07D401/06

Abstract: PROBLEM TO BE SOLVED: To obtain a compound capable of resisting dysgnosia with aging and ameliorating a recognition process, having analgesic characteristics. SOLUTION: This compound is represented by formula (I) [A is pyridine, or the like; R2 is hydrogen atom, or the like; R3 is hydroxy group, or the like; R4 is phenyl group, or the like; R1 is hydrogen atom, or the like; R5 is a five- or six-membered ring which may contain a nitrogen atom combined with the ring A and another hetero atom selected from sulfur, oxygen and nitrogen; R6 is hydrogen atom, or the like], its enantiomer, a diastereoisomer, pharmacologically acceptable acid, base or their addition salts. The method for producing the compound is provided. The medicine composition comprises the compound.

公开(公告)号：JP2002069046A

公开(公告)日：2002-03-08

申请号：JP2001191541

申请日：2001-06-25

Applicant: SERVIER LAB

Inventor： GOLDSTEIN SOLO ,  GUILLONNEAU CLAUDE ,  CHARTON YVES ,  LOCKHART BRIAN ,  LESTAGE PIERRE

IPC: C07D295/08 ,  A61K31/10 ,  A61K31/13 ,  A61K31/133 ,  A61K31/15 ,  A61K31/16 ,  A61K31/215 ,  A61K31/22 ,  A61K31/221 ,  A61K31/223 ,  A61K31/27 ,  A61K31/40 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/4406 ,  A61K31/445 ,  A61K31/455 ,  A61P25/00 ,  A61P25/14 ,  A61P25/16 ,  A61P25/18 ,  A61P25/20 ,  A61P25/24 ,  A61P25/28 ,  A61P25/34 ,  A61P29/00 ,  A61P29/02 ,  A61P43/00 ,  C07C62/02 ,  C07C209/00 ,  C07C211/37 ,  C07C213/00 ,  C07C213/02 ,  C07C213/06 ,  C07C215/20 ,  C07C215/42 ,  C07C217/44 ,  C07C217/52 ,  C07C219/18 ,  C07C219/20 ,  C07C219/24 ,  C07C269/00 ,  C07C269/02 ,  C07C271/12 ,  C07C271/22 ,  C07C271/24 ,  C07C271/34 ,  C07C319/14 ,  C07C321/28 ,  C07C323/26 ,  C07C323/33 ,  C07D213/30 ,  C07D213/38 ,  C07D213/53 ,  C07D213/65 ,  C07D213/70 ,  C07D213/80 ,  C07D213/803 ,  C07D295/096 ,  C07D417/12

Abstract: PROBLEM TO BE SOLVED: To provide a new 1,1- and 1,2-disubstituted cyclopropane compound having specific interaction with central nicotinic receptors of type α4β2. SOLUTION: This compound is represented by formula (1), and concretely exemplified by 2-[1-(dimethylamino)cyclopropyl] ethylmethylcarbamate. The compound is useful for treatment of deficiencies of memory associated with cerebral ageing and neurodegenerative diseases.

公开(公告)号：WO2011070253A8

公开(公告)日：2012-08-02

申请号：PCT/FR2010000823

申请日：2010-12-08

Applicant: SERVIER LAB ,  CASARA PATRICK ,  CHOLLET ANNE-MARIE ,  DHAINAUT ALAIN ,  HENLIN JEAN-MICHEL ,  LESTAGE PIERRE ,  PANAYI FANY

Inventor： CASARA PATRICK ,  CHOLLET ANNE-MARIE ,  DHAINAUT ALAIN ,  HENLIN JEAN-MICHEL ,  LESTAGE PIERRE ,  PANAYI FANY

IPC: C07D209/52 ,  A61K31/403 ,  A61P25/00

CPC classification number: C07D209/52

Abstract: The invention relates to the compounds of formula (I), where: ALK is an alkylene chain, and W is a grouping of formula (II) or formula (III), where R and R' are as defined in the description. The invention can be used as a drug.

Abstract translation: 本发明涉及式（I）化合物，其中：ALK是亚烷基链，W是式（II）或式（III）的基团，其中R和R'如说明书中所定义。 本发明可用作药物。

公开(公告)号：WO0200638A2

公开(公告)日：2002-01-03

申请号：PCT/IB0101535

申请日：2001-06-27

Applicant: INST MATERIA MEDICA ,  SERVIER LAB ,  GUO ZONGRU ,  CHU FENGMING ,  ZHANG JUNTIAN ,  YANG GUANGZHONG ,  XU BAILING ,  NIU XINYI ,  REN ZHIHONG ,  LESTAGE PIERRE ,  RENARD PIERRE

Inventor： GUO ZONGRU ,  CHU FENGMING ,  ZHANG JUNTIAN ,  YANG GUANGZHONG ,  XU BAILING ,  NIU XINYI ,  REN ZHIHONG ,  LESTAGE PIERRE ,  RENARD PIERRE

IPC: C07D307/88 ,  A61K31/34 ,  A61K31/365 ,  A61P9/10 ,  A61P25/00 ,  A61P25/08 ,  A61P25/16 ,  A61P25/28 ,  C07D239/42 ,  C07D471/04 ,  C07D487/04 ,  C07D307/00

CPC classification number: C07D239/42 ,  C07D471/04 ,  C07D487/04

Abstract: The invention relates to compounds of formula (I): wherein R represents an alkyl or ureido group, R represents an alkyl group or a hydrogen atom, or R and R together form a 5- or 6-membered ring, R represents a group CN, NO2, NRaR'a, NRaSO2,R'aCZR or CZNRaR'a, R represents a hydrogen atom or a group R .

Abstract translation: 本发明涉及式（I）化合物：其中R 1表示烷基或脲基，R 2表示烷基或氢原子，或R 1和R 2一起形成5 - 或6-元环，R 3表示CN，NO 2，NR a R aa，NR a SO 2，R'CZR 5或CZNR a R aa，R 4表示氢原子或基团R 3， 。

公开(公告)号：JP2006342158A

公开(公告)日：2006-12-21

申请号：JP2006133321

申请日：2006-05-12

Applicant: SERVIER LAB

Inventor： DESOS PATRICE ,  CORDI ALEX ,  LESTAGE PIERRE

IPC: C07D213/74 ,  A61K31/496 ,  A61K31/5377 ,  A61P3/04 ,  A61P25/00 ,  A61P25/02 ,  A61P25/08 ,  A61P25/14 ,  A61P25/16 ,  A61P25/28 ,  A61P43/00 ,  C07B61/00

Abstract: PROBLEM TO BE SOLVED: To provide an antagonist of a new H 3 type central histamine receptor. SOLUTION: The compound represented by formula (I) is provided [wherein R 1 is an NR 3 SO 2 R 4 (R 3 is H or an alkyl, and R 4 is an alky, an aryl or NR 5 R 6 ); and R 2 is an alkyl, a cycloalkyl or a cycloalkylalkyl]. COPYRIGHT: (C)2007,JPO&INPIT

公开(公告)号：WO2004048340A8

公开(公告)日：2005-07-07

申请号：PCT/EP0314841

申请日：2003-11-26

Applicant: SHANGHAI INST MATERIA MEDICA ,  SERVIER LAB ,  QIN GUO-WEI ,  TANG XI-CAN ,  WANG RUI ,  ZHOU TIAN-XI ,  LESTAGE PIERRE ,  CAIGNARD DANIEL-HENRI ,  RENARD PIERRE

Inventor： QIN GUO-WEI ,  TANG XI-CAN ,  WANG RUI ,  ZHOU TIAN-XI ,  LESTAGE PIERRE ,  CAIGNARD DANIEL-HENRI ,  RENARD PIERRE

IPC: C07D221/28 ,  A61K31/485 ,  C07D489/00

CPC classification number: C07D221/28

Abstract: The invention relates to sinomenine and compounds thereof and also to compounds of formula (I), wherein R1 represents an alkyl group; R2 represents a hydrogen atom or an alkylcarbonyl group, an haloalkylcarbonyl group or an arylcarbonyl; Y represents a group (II), (III) or (IV); R3 ,R4, R'4, R5, R'5 and R6 are as defined in the description; and X represents a halogen atom. Medicaments.

Abstract translation: 本发明涉及青藤碱及其化合物，还涉及式（I）化合物，其中R 1表示烷基; R2表示氢原子或烷基羰基，卤代烷基羰基或芳基羰基; Y代表（II），（III）或（IV）; R3，R4，R'4，R5，R'5和R6如说明书中所定义; X表示卤素原子。 药物。

公开(公告)号：WO2007012761A8

公开(公告)日：2007-12-21

申请号：PCT/FR2006001831

申请日：2006-07-27

Applicant: SERVIER LAB ,  GOLDSTEIN SOLO ,  GUILLONNEAU CLAUDE ,  CHARTON YVES ,  LOCKHART BRIAN ,  LESTAGE PIERRE

Inventor： GOLDSTEIN SOLO ,  GUILLONNEAU CLAUDE ,  CHARTON YVES ,  LOCKHART BRIAN ,  LESTAGE PIERRE

IPC: C07D213/74 ,  A61K31/44 ,  A61P25/00

CPC classification number: C07D213/74

Abstract: The invention concerns compounds of formula (I), wherein: n represents an integer between 1 and 6 inclusively; R 1 and R 2 represent a hydrogen atom a (C 1 -C 6 ) alkyl or (C 1 -C 6 ) arylalkyl group; R 3 and R 4 represent a hydrogen atom, a (C 1 -C 6 ) alkyl group; R 5 and R 6 represent a hydrogen atom, a (C 1 -C 6 ) alkyl group, halogen, hydroxy, (C 1 -C 6 ) alkoxy, cyano, nitro, (C 2 -C 6 ) acyl, (C 1 -C 6 ) alkoxycarbonyl, (C 1 -C 6 ) trihalogenoalkyl, (C 1 -C 6 ) trihalogenoalkoxy or amino optionally substituted; R 7 represents a hydrogen atom, a (C 1 -C 6 ) alkyl group or arylalkyl. The invention is useful for preparing medicines.

Abstract translation: 本发明涉及式（I）的化合物，其中：n表示1至6的整数; R 1和R 2代表氢原子a（C 1 -C 6）烷基或（C 1 -C 6烷基） 1〜6）芳基烷基; R 3和R 4代表氢原子，（C 1 -C 6）烷基;并且R 4代表氢原子，（C 1 -C 6） R 5和R 6代表氢原子，（C 1 -C 6）6烷基，卤素 ，羟基，（C 1 -C 6）烷氧基，氰基，硝基，（C≡C2 -C 6） ）酰基，（C 1 -C 6）烷氧基羰基，（C 1 -C 6）亚烷基，（（C 1 -C 6） C1-C6）任选取代的三卤代烷氧基或氨基; R 7代表氢原子，（C 1 -C 6）烷基或芳基烷基。 本发明对于制备药物是有用的。

公开(公告)号：WO0200638A8

公开(公告)日：2003-08-28

申请号：PCT/IB0101535

申请日：2001-06-27

Applicant: INST MATERIA MEDICA ,  SERVIER LAB ,  GUO ZONGRU ,  CHU FENGMING ,  ZHANG JUNTIAN ,  YANG GUANGZHONG ,  XU BAILING ,  NIU XINYI ,  REN ZHIHONG ,  LESTAGE PIERRE ,  RENARD PIERRE

Inventor： GUO ZONGRU ,  CHU FENGMING ,  ZHANG JUNTIAN ,  YANG GUANGZHONG ,  XU BAILING ,  NIU XINYI ,  REN ZHIHONG ,  LESTAGE PIERRE ,  RENARD PIERRE

IPC: C07D307/88 ,  A61K31/34 ,  A61K31/365 ,  A61P9/10 ,  A61P25/00 ,  A61P25/08 ,  A61P25/16 ,  A61P25/28 ,  C07D239/42 ,  C07D471/04 ,  C07D487/04

CPC classification number: C07D239/42 ,  C07D471/04 ,  C07D487/04

Abstract: The invention relates to compounds of formula (I): wherein R represents an alkyl or ureido group, R represents an alkyl group or a hydrogen atom, or R and R together form a 5- or 6-membered ring, R represents a group CN, NO2, NRaR'a, NRaSO2,R'aCZR or CZNRaR'a, R represents a hydrogen atom or a group R .

Abstract translation: 本发明涉及式（I）化合物：其中R 1表示烷基或脲基，R 2表示烷基或氢原子，或R 1和R 2一起形成5 - 或6-元环，R 3表示CN，NO 2，NR a R aa，NR a SO 2，R'CZR 5或CZNR a R aa，R 4表示氢原子或基团R 3， 。

公开(公告)号：FR3034019B1

公开(公告)日：2017-03-17

申请号：FR1552563

申请日：2015-03-26

Applicant: SERVIER LAB

Inventor： BRETIN SYLVIE ,  DANOBER LAURENCE ,  LESTAGE PIERRE

IPC: A61K31/536 ,  A61K31/343 ,  A61K31/445 ,  A61P25/22 ,  A61P25/24

公开(公告)号：CY1110944T1

公开(公告)日：2015-06-10

申请号：CY101101087

申请日：2010-11-29

Applicant: SERVIER LAB

Inventor： FRANCOTTE PIERRE ,  DE TULLIO PASCAL ,  PIROTTE BERNARD ,  DANOBER LAURENCE ,  LESTAGE PIERRE ,  CAIGNARD DANIEL-HENRI

IPC: C07D285/28 ,  A61K31/549 ,  A61P25/00

Abstract: Ενώσειςτουτύπου (I) :